These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

897 related articles for article (PubMed ID: 33027976)

  • 41. Immunoediting Dynamics in Glioblastoma: Implications for Immunotherapy Approaches.
    Amin T; Hossain A; Jerin N; Mahmud I; Rahman MA; Rafiqul Islam SM; Islam SMBU
    Cancer Control; 2024; 31():10732748241290067. PubMed ID: 39353594
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Safety of available immunotherapy for the treatment of glioblastoma.
    Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
    Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma.
    Majd N; de Groot J
    Expert Opin Pharmacother; 2019 Sep; 20(13):1609-1624. PubMed ID: 31264484
    [No Abstract]   [Full Text] [Related]  

  • 44. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
    Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
    J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent advances and future of immunotherapy for glioblastoma.
    Kamran N; Calinescu A; Candolfi M; Chandran M; Mineharu Y; Asad AS; Koschmann C; Nunez FJ; Lowenstein PR; Castro MG
    Expert Opin Biol Ther; 2016 Oct; 16(10):1245-64. PubMed ID: 27411023
    [TBL] [Abstract][Full Text] [Related]  

  • 46. GBM Immunotherapy: Macrophage Impacts.
    Loginova N; Aniskin D; Timashev P; Ulasov I; Kharwar RK
    Immunol Invest; 2024 Jul; 53(5):730-751. PubMed ID: 38634572
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunotherapy for Glioblastoma: Current Progress and Challenges.
    Yu MW; Quail DF
    Front Immunol; 2021; 12():676301. PubMed ID: 34054867
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunotherapy for glioblastoma: the promise of combination strategies.
    Bausart M; Préat V; Malfanti A
    J Exp Clin Cancer Res; 2022 Jan; 41(1):35. PubMed ID: 35078492
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Why Don't the Mutant Cells That Evade DNA Repair Cause Cancer More Frequently? Importance of the Innate Immune System in the Tumor Microenvironment.
    Mohapatra S; Cafiero J; Kashfi K; Mehta P; Banerjee P
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902456
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics.
    Ye Z; Ai X; Zhao L; Fei F; Wang P; Zhou S
    Oncogene; 2021 Oct; 40(42):6059-6070. PubMed ID: 34556813
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting EGFRvIII for glioblastoma multiforme.
    Yang J; Yan J; Liu B
    Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape.
    Inocencio JF; Mitrasinovic S; Asad M; Parney IF; Zang X; Himes BT
    Front Immunol; 2024; 15():1424396. PubMed ID: 39346924
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Emerging therapies for glioblastoma: current state and future directions.
    Rong L; Li N; Zhang Z
    J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pericytes in Glioblastomas: Multifaceted Role Within Tumor Microenvironments and Potential for Therapeutic Interventions.
    Sattiraju A; Mintz A
    Adv Exp Med Biol; 2019; 1147():65-91. PubMed ID: 31147872
    [TBL] [Abstract][Full Text] [Related]  

  • 55. STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models.
    Berger G; Knelson EH; Jimenez-Macias JL; Nowicki MO; Han S; Panagioti E; Lizotte PH; Adu-Berchie K; Stafford A; Dimitrakakis N; Zhou L; Chiocca EA; Mooney DJ; Barbie DA; Lawler SE
    Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2111003119. PubMed ID: 35787058
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
    Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
    J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities.
    Maccari M; Baek C; Caccese M; Mandruzzato S; Fiorentino A; Internò V; Bosio A; Cerretti G; Padovan M; Idbaih A; Lombardi G
    Oncologist; 2024 Apr; 29(4):289-302. PubMed ID: 38048782
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Single-cell atlas reveals the immunosuppressive microenvironment and Treg cells landscapes in recurrent Glioblastoma.
    Wang X; Ge Y; Hou Y; Wang X; Yan Z; Li Y; Dong L; She L; Tang C; Wei M; Zhang H
    Cancer Gene Ther; 2024 May; 31(5):790-801. PubMed ID: 38429367
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Macrophages and microglia: the cerberus of glioblastoma.
    Buonfiglioli A; Hambardzumyan D
    Acta Neuropathol Commun; 2021 Mar; 9(1):54. PubMed ID: 33766119
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination of tumor antigen drainage and immune activation to promote a cancer-immunity cycle against glioblastoma.
    Xu H; Zhao X; Luo J
    Cell Mol Life Sci; 2024 Jun; 81(1):275. PubMed ID: 38907858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.